Tonix Pharmaceuticals Holding Corp.’s TNXP share price has surged by 32.48%, which has investors questioning if this is right time to sell.

BACKGROUND: Despite the high morbidity and mortality of heart failure with preserved ejection fraction (HFpEF), treatment ...

Tonix Pharmaceuticals Holding Corp.’s TNXP share price has dipped by 19.78%, which has investors questioning if this is right ...

August 15, 2025, is the FDA PDUFA goal date for TNX-102 SL for the management of fibromyalgia; If approved, TNX-102 SL would become the first new ...

Tonix Pharmaceuticals (NASDAQ: TNXP) , a biopharmaceutical company developing innovative vaccines, is advancing TNX-801, a live, minimally replicatin ...

New data showed that a single dose of a tumor-selective triple knockout (“3KO”) RT virus with a specific immunotherapeutic payload (undisclosed) has dramatically altered the tumor microenvironment, ...

Tonix Pharmaceuticals (NASDAQ: TNXP) announced its fourth-quarter and full-year 2024 financial results, alongside key operational updates. The compan ...

August 15, 2025, is the FDA PDUFA goal date for TNX-102 SL for the management of fibromyalgia; If approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more than 15 years ...

It will do this by developing TCR-T TSC-102-A0301, which is being used to go after CD45 on HLA-A*03:01. An IND filing for this therapy is expected to happen in the 2nd half of 2025. According to ...

Furthermore, ASCs were negative for the markers CD31/CD45 but positive for the stem cell markers CD34, CD73, CD90, and CD105 (Supplementary Figure 2). Hypoxia Reduces the Proliferation of ASCs We ...